Frequently asked questions about MPA
Every medical claim on this page links to its source. Last updated 15 November 2026. Educational information, not medical advice.
Does everyone with MPA need dialysis?
No. Some people have no detectable kidney involvement. Others respond to treatment with preserved or improved kidney function. Dialysis may be temporary during a severe flare, or long term if the kidneys do not recover enough.1,2,3
How are the two kinds of dialysis different?
Hemodialysis filters blood outside the body through a machine. Peritoneal dialysis uses the lining of the belly. Both can be used while waiting for a transplant, and some people switch as health or preferences change.2 See dialysis.
Can someone get a transplant before dialysis?
Yes, if they are suitable, evaluated, and able to receive a kidney before dialysis is needed. A living donor can make timing easier. Ask the transplant program when to begin evaluation.4,5,6
Can MPA come back in a transplanted kidney?
Yes, including years later. A rise in creatinine or new blood or protein in urine can have several causes, so the team uses context and sometimes a biopsy to tell recurrence from rejection, infection or drug effects.1,7,8
Do ANCA levels tell when to start treatment?
ANCA tests help with diagnosis and can inform follow-up. Treatment decisions depend on symptoms, organ findings and kidney tests. A positive result, or a rise, usually does not on its own prove active disease.1,9
Can pregnancy happen after a transplant?
Yes. Planning ahead with nephrology or transplant, rheumatology and maternal-fetal medicine helps check kidney stability, medicines and risks. Pregnancy on dialysis also happens and needs specialist planning.10,11,12
Is MPA inherited? Is it curable?
Research has found genetic susceptibility, but MPA generally does not follow a predictable single-gene pattern. Current treatment aims for remission and preventing damage. No published evidence establishes a cure. Experimental therapies are being studied; see latest research.1,13,14
Sources
- KDIGO: KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis [doc ref 1]
- NIDDK (NIH): Kidney failure: treatment comparison chart [doc ref 45]
- KDOQI / KDIGO: KDOQI commentary on the KDIGO 2024 ANCA vasculitis guideline [doc ref 47]
- KDIGO: KDIGO 2024 Clinical Practice Guideline for chronic kidney disease [doc ref 48]
- NIDDK (NIH): Kidney transplant [doc ref 49]
- HRSA / OPTN: OPTN policies [doc ref 50]
- Kidney International Reports (2025): Outcomes after kidney transplantation in ANCA-associated renal vasculitis (French multicenter study) [doc ref 3]
- Clinical Journal of the American Society of Nephrology (2026): Kidney transplantation in childhood-onset ANCA-associated vasculitis: long-term outcomes [doc ref 31]
- Rheumatology (2025): 2025 British Society for Rheumatology recommendations for ANCA-associated vasculitis [doc ref 40]
- Society for Maternal-Fetal Medicine: SMFM Consult Series #66: pregnancy after transplant [doc ref 4]
- BMC Nephrology (2019): Clinical practice guideline on pregnancy and renal disease [doc ref 14]
- Journal of Nephrology (2025): Pregnancy after kidney transplantation: registry data from three continents [doc ref 15]
- EBioMedicine (2026): Exploration of the genetic architecture of ANCA-associated vasculitis [doc ref 33]
- ClinicalTrials.gov: NCT07388277: CC-97540 (CD19 CAR T) in ANCA-associated vasculitis [doc ref 22]
Links checked 15 November 2026. Full list: all sources.